MapQuant Dx(TM) Genomic Grade is made available for diagnostic use in Europe by Ipsogen through its MapQuant Dx(TM) testing solution including: MapQuant Dx(TM) Path Kit, CE-marked, ensuring easy sampling, RNA-preservation and shipping at ambient temperature; ISO-17025 MapQuant Dx(TM) Lab Services performed by DNAVision SA (Gosselies, Belgium) using Affymetrix GeneChip(R) Systems 3000Dx2 (GCS3000Dx2) platform ensuring highly reproducible sample processing; and MapQuant Dx(TM) CE-compliant software, ensuring highly reliable quality controls, data processing and Genomic Grade index computation. MapQuant Dx(TM) testing solution is developed under the innovation support program of the French Health Products Safety Agency (Afssaps). Commercialization in the United States depends on FDA's (Food and Drug Administration) formal approval.
Ipsogen is a cancer profiler that develops and markets molecular diagnostic assays designed to map diseases and guide patients and clinicians decisions along the complex therapeutic path.
With more than 60 tests already used routinely worldwide for the diagnosis, prognosis and follow-up of thousands of patients with leukemia, Ipsogen is now also targeting breast cancer. Its initial goal will be to provide diagnostic information that has been inaccessible until now. Ipsogen is also a partner of choice for biopharmaceutical companies committed to revolutionary theranostics.
Strengthened by its first-rate scientific, clinical and technological
partnerships, in addition to its highly-skilled multidisciplinary team in
|SOURCE Ipsogen SA|
Copyright©2008 PR Newswire.
All rights reserved